{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:36:47Z","timestamp":1787071007461,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>There is no consensus for palliative chemotherapy regimen in metastatic gallbladder cancer. We did a retrospective study to compare the treatment outcome in patients of metastatic gallbladder cancer treated with either gemcitabine + cisplatin (regimen A) or oral capecitabine (regimen B) alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods:<\/jats:title>\n                    <jats:p>A total of 67 patients between January 2015 and September 15 treated with either regimen A or regimen B were retrospectively evaluated. Statistical analysis was done in June 2019. Kaplan\u2013Meir and Log rank test were used to compare survival between two arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Out of 67 patients, 31\/67 (46%) received regimen A, and 36\/67 (54%) received regimen B. Male to female ratio was 1:3. About 42% patients in regimen A and 20% in regimen B required palliative stenting. Median number of chemotherapy cycles was 4 in both regimen A (range 1-&gt;6) and regimen B (range 1-&gt;6). Patients receiving 3 cycles and 6 cycles of chemotherapy in regimen A and regimen B was 68% and 31% versus 70% and 63%, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.86). Response assessment as any response (complete response + partial response + disease was stable) after 3 cycles and 6 cycles was 71% and 57% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.20), 44% and 39% (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.29), in regimen A and B, respectively. Median survival was 23 weeks (range 2\u2013106 weeks) in regimen A and 15 weeks (range 4\u201383 weeks) in regimen B (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.40).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The present study shows gemcitabine and cisplatin has nonsignificant better survival compared to oral capecitabine. However, oral capecitabine is more convenient and easy to administer. Studies with larger sample size are needed to further establish the standard chemotherapy guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_896_19","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T12:03:16Z","timestamp":1634904196000},"page":"939-945","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A comparative study of gemcitabine and cisplatin versus oral capecitabine alone in metastatic gallbladder cancer"],"prefix":"10.4103","volume":"18","author":[{"given":"Deepak","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagun","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaleen","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punita","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20241021","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/ijc.21683","article-title":"Gallbladder cancer worldwide: Geographical distribution and risk factors","volume":"118","author":"Randi","year":"2006","journal-title":"Int J Cancer"},{"key":"R2-11-20241021","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R3-11-20241021","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/ijc.21109","article-title":"Geographic pathology revisited: Development of an atlas of cancer in India","volume":"116","author":"Nandakumar","year":"2005","journal-title":"Int J Cancer"},{"key":"R6-11-20241021","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1440-1746.2005.03576.x","article-title":"Gallbladder cancer in India: A dismal picture","volume":"20","author":"Batra","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"R7-11-20241021","first-page":"2","article-title":"Incidence of gallbladder cancer in rural and semi urban population of north central India: A first insight","volume":"7","author":"Barbhuiya","year":"2009","journal-title":"Internet J Epidemiol"},{"key":"R8-11-20241021","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","article-title":"Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: A multicentre randomised phase II study-The UK ABC-01 Study","volume":"101","author":"Valle","year":"2009","journal-title":"Br J Cancer"},{"key":"R9-11-20241021","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R11-11-20241021","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/sj.bjc.6601736","article-title":"A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer","volume":"90","author":"Doval","year":"2004","journal-title":"British journal of cancer"},{"key":"R12-11-20241021","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: A GERCOR study","volume":"15","author":"Andr\u00e9","year":"2004","journal-title":"Ann Oncol"},{"key":"R13-11-20241021","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jso.2930280109","article-title":"Primary carcinoma of the gall bladder: A review of a 16-year period at the University Hospital","volume":"28","author":"Shukla","year":"1985","journal-title":"J Surg Oncol"},{"key":"R14-11-20241021","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1023\/A:1010652105532","article-title":"Carcinoma of the gallbladder: A retrospective review of 99 cases","volume":"46","author":"Pandey","year":"2001","journal-title":"Dig Dis Sci"},{"key":"R15-11-20241021","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejso.2011.03.135","article-title":"Prognostic value of jaundice in patients with gallbladder cancer by the AFC-GBC-2009 study group","volume":"37","author":"Regimbeau","year":"2011","journal-title":"Eur J Surg Oncol"},{"key":"R16-11-20241021","first-page":"131","article-title":"Carcinoma gallbladder-epidemiological trends in a tertiary hospital in North India","volume":"4","author":"Lal","year":"2018","journal-title":"Arch Surg Oncol"},{"key":"R17-11-20241021","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1300::AID-CNCR19>3.0.CO;2-4","article-title":"Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.)","volume":"78","author":"Gebbia","year":"1996","journal-title":"Cancer"},{"key":"R18-11-20241021","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1023\/A:1008241008379","article-title":"Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin","volume":"9","author":"Ducreux","year":"1998","journal-title":"Ann Oncol"},{"key":"R19-11-20241021","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/annonc\/mdg281","article-title":"Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer","volume":"14","author":"Kim","year":"2003","journal-title":"Ann Oncol"},{"key":"R20-11-20241021","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","article-title":"Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial","volume":"23","author":"Knox","year":"2005","journal-title":"J Clin Oncol"},{"key":"R21-11-20241021","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cncr.20753","article-title":"Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: A North Central Cancer Treatment Group phase II trial","volume":"103","author":"Alberts","year":"2005","journal-title":"Cancer"},{"key":"R22-11-20241021","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjc.6604178","article-title":"Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: A prospective multicentre phase II trial","volume":"98","author":"Nehls","year":"2008","journal-title":"Br J Cancer"},{"key":"R23-11-20241021","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13104-015-1778-4","article-title":"A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract","volume":"9","author":"Graham","year":"2016","journal-title":"BMC Res Notes"},{"key":"R24-11-20241021","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1023\/A:1012543223020","article-title":"A phase II study of gemcitabine in gallbladder carcinoma","volume":"12","author":"Gallardo","year":"2001","journal-title":"Ann Oncol"},{"key":"R25-11-20241021","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: A phase II study","volume":"99","author":"Andr\u00e9","year":"2008","journal-title":"Br J Cancer"},{"key":"R26-11-20241021","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: A comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"R27-11-20241021","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/cncr.20368","article-title":"Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma","volume":"101","author":"Patt","year":"2004","journal-title":"Cancer"},{"key":"R28-11-20241021","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/annonc\/mdz058","article-title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: A multicenter, open-label, randomized, phase III, noninferiority trial","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_896_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:16Z","timestamp":1787067616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_896_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_896_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}